ArticlePloS one2025
Acupuncture (Jin's Three-Needle) versus sham acupuncture in treating mild-to-moderate depression: Study protocol for randomized clinical trial.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMild-to-moderate depression is an increasing public health problem worldwide, which is more prevalent than major depression but has received less attention Currently, no existing highly effective pharmacological treatments with minimal adverse reactions are available for this condition. Jin's Three-Needle Acupuncture (JTN) may be an alternative treatment option for mild-to-moderate depression patients.
methodsThis is a prospective, parallel-arm, single-blind, randomized controlled trial. We plan to enroll 106 participants with mild-to-moderate depression, randomly assigning them to receive either JTN or sham acupuncture (SA) in a 1:1 ratio. All participants will receive the JTN treatment or SA treatment for 8 weeks (3 per week). The primary outcome will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). Secondary outcomes will include the Self-Rating Depression Scale (SDS), Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety Scale (HAMA), Self-Rating Anxiety Scale (SAS), and the Traditional Chinese Medicine Syndrome Score Scale (TCMSS). Evaluations will be performed at baseline and at weeks 4, 6, and 8 after treatment initiation. Statistical analyses will be conducted on both the intention-to-treat (ITT) and per-protocol (PP) datasets. DISCUSSION: This study aims to provide high-quality evidence regarding the efficacy and safety of JTN as a treatment for mild-to-moderate depression. Additionally, the mechanisms underlying the effects of JTN in treating mild-to-moderate depression will be explored.
trial registrationThe trial registered with the International Traditional Medicine Clinical Trial Registry (ITMCTR2024000872). URL: https://www.itmctr.ccebtcm.org.cn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.